255893-57-3

Basic information

• Product Name: 1-(3,4-Difluorophenyl)piperazine
• Synonyms: 1-(3,4-Difluorophenyl)piperazine97%;1-(3,4-Difluorophenyl)piperazine;Piperazine,1-(3,4-difluorophenyl)-
• CAS NO: 255893-57-3
• Molecular Formula: C₁₀H₁₂F₂N₂
• Molecular Weight: 198.21
• Mol File: 255893-57-3.mol

Chemical Properties

• Boiling Point: 107-110
• Flash Point: 141.9 °C
• Appearance: /
• Density: 1.193 g/cm³
• Vapor Pressure: 0.000579mmHg at 25°C
• Refractive Index: 1.511
• CAS DataBase Reference: 1-(3,4-Difluorophenyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3,4-Difluorophenyl)piperazine(255893-57-3)
• EPA Substance Registry System: 1-(3,4-Difluorophenyl)piperazine(255893-57-3)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 255893-57-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(3,4-Difluorophenyl)piperazine is utilized as a pharmacological agent for its activity as a serotonin receptor agonist, which makes it a potential treatment option for a range of medical conditions that can be modulated by interacting with serotonin receptors.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 1-(3,4-Difluorophenyl)piperazine serves as a valuable compound for research into the development of new drugs. Its unique structure and properties allow scientists to explore its potential in creating novel therapeutic agents.
Used in Drug Synthesis as a Precursor:
1-(3,4-Difluorophenyl)piperazine is also used as a precursor in the synthesis of other pharmaceutical compounds. Its role in the production process is crucial for creating new medications that can address unmet medical needs.

InChI:InChI=1/C10H12F2N2/c11-9-2-1-8(7-10(9)12)14-5-3-13-4-6-14/h1-2,7,13H,3-6H2

Upstream product

• 348-61-8 1-bromo-3,4-difluorobenzene 
• 64248-58-4 1,2-difluoro-4-iodo-benzene 
• 110-85-0 piperazine 
• 367-23-7 1,2,4-trifluorobenzene 
• 646518-38-9 1-benzyl-4-(3,4-difluorophenyl)-piperazine 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 3863-11-4 3,4-difluoroaniline 

Downstream Products

• 1027492-71-2 {2-amino-4-[(4-(3,4-difluorophenyl)piperazin-1-yl)methyl]thiophen-3-yl}(4-chlorophenyl)methanone 
• 1355155-98-4 2-{3-(4-chlorobenzoyl)-4-[(4-(3,4-difluorophenyl)piperazin-1-yl)methyl]thiophen-2-yl}-isoindole-1,3-dione 
• 646518-39-0 (4S,4aS,8aR)-4-[4-(3,4-Difluoro-phenyl)-piperazine-1-carbonyl]-octahydro-isoquinoline-2-carboxylic acid tert-butyl ester 
• 524743-90-6 C₁₃H₁₄F₂N₂O 
• 1145683-91-5 2-{5-[4-(3,4-difluorophenyl)piperazin-1-yl]-4'-trifluoromethylbiphenyl-3-yl}-4-methylpentanoic acid ethyl ester 
• 1016228-19-5 C₂₆H₂₇BrF₂N₄O 
• 1016228-20-8 C₂₇H₂₉BrF₂N₄O 

Relevant articles and documents

The development of a practical synthesis of the potent and selective somatostatin sst3 receptor antagonist [4-(3,4-difluoro-phenyl)- piperazine-1-yl]-{(4S,4aS,8aR)-2[(S)-3-(6-methoxy-pyridin-3-yl)-2-methyl-propyl] -decahydroisoquinoline-4-yl}-methanone (NVP-ACQ090)

The decahydroisoquinoline derivative NVP-ACQ090 is a potent and selective antagonist at the somatostatin sst3 receptor. The original research synthesis of NVP-ACQ090 comprises a main chain of nine linear steps and two side chains of three and steps, respectively. This synthesis is highly convergent, but very complex and expensive, and involves several reagents that are not acceptable for a large scale synthesis. In chemical development, all the unacceptables could be replaced, and the overall efficiency of the synthesis was much improved.

INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE

Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic disorders, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.

Microwave-assisted amination from fluorobenzenes without catalyst and strong base

A facile and versatile amination of fluorobenzenes has been developed in good to excellent yields under microwave irradiation in N-methylpyrrolidinone (NMP) without strong base and catalyst. The presence of additional halogen atom(s) enhanced the leaving ability of fluorine and meta fluorine gave higher activation than the ortho. It is remarkable that 1,2,3-trifluorobenzene, 1,2,4-trifluorobenzene and 1,2,4,5-tetrafluorobenzene can produce the regioselective mono-substituted products.

Potent, selective, and orally active adenosine A2A receptor antagonists: Arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines

Antagonism of the adenosine A2A receptor offers great promise in the treatment of Parkinson's disease. Employing the known pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine A2A antagonist SCH 58261 as a starting point, we identified the potent and selective (vs. A1) antagonist 11 h, orally active in the rat haloperidol-induced catalepsy model. We further optimized this lead to the methoxyethoxyethyl ether 12a (SCH 420814), which shows broad selectivity, good pharmacokinetic properties, and excellent in vivo activity.

Substituted piperazines

Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

SUBSTITUTED DIHYDROCHINAZOLINES HAVING ANTIVIRAL PROPERTIES

The invention relates to substituted dihydrochinazolines of formula (I), methods for the production thereof, and the use thereof for producing medicaments used for treating and/or preventing diseases, particularly as antiviral agents, especially against cytomegaloviruses.

1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS

Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.